Literature DB >> 16419002

[Treatment of lupus nephritis].

A Ferrantelli1, L Bono, C Tortorici, R Termini, C Giammarresi, U Rotolo.   

Abstract

SLE begins with renal symptoms in about 30-50% of the patients and after 10 years over 70% of them has complications. In the last years the medical therapy improved the outcome of SLE and its complications. Presently, the survival for lupus nephritis is 80% after five years. The nephritis treatment is divided into remission-inducing treatment that is followed by remission-maintaining treatment. Moreover, it is considered the therapy for preventing or reducing toxic and side-effects from drugs and the therapy for flare-ups. To initiate the specific therapy is important to consider the histological class (WHO). In the remission-inducing treatment steroids are used alone for 3-6 months in class IIB or in association with cyclophosphamide in classes III-IV and V and for flare-ups. For remission-maintaining treatment steroids are used in association with azathioprine. The drugs improved the outcome of nephritis but produced side-effects that determined the suspension of the drug and/or reduction of dosage and/or the use of other drugs like mycophenolate mofetil or rituximab.

Entities:  

Mesh:

Year:  2005        PMID: 16419002

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  2 in total

1.  A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.

Authors:  Alaa Sabry; Hamdy Abo-Zenah; Tarek Medhat; Hussein Sheashaa; Khaled Mahmoud; Amr El-Huseini
Journal:  Int Urol Nephrol       Date:  2008-01-24       Impact factor: 2.370

2.  Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis.

Authors:  Zahra Rezaieyazdi; Tahmine Tavakoli; Mohammad Khajehdaluee; Shahram Honarmand
Journal:  Springerplus       Date:  2014-10-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.